SCHEMBL536589

SCHEMBL536589

COC(=O)c1cccc2[nH]cnc12

nearest known ligand 0.64

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.64
PKN1 Q16512 1/20 0.50
PKN2 Q16513 1/20 0.50
NR4A2 P43354 2/20 0.47
CREBBP Q92793 1/20 0.47
RIPK1 Q13546 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31529624 0.83 PARP1 (0.59) PARP1
SCHEMBL534252 0.83 PARP1 (0.59) PARP1
SCHEMBL1382494 0.83 TSHR (0.56) PARP1
SCHEMBL27464431 0.82 PARP1 (0.57) PARP1
SCHEMBL112629 0.81 PARP1 (0.70) PARP1
SCHEMBL5274069 0.81 PARP1 (0.56) PARP1
SCHEMBL29698487 0.81 PARP1 (0.64) PARP1PKN1PKN2
SCHEMBL26177802 0.80 PARP1 (0.59) PARP1
SCHEMBL30401646 0.80 PARP1 (0.56) PARP1NR4A2CREBBP
SCHEMBL666431 0.80 PARP1 (0.56) PARP1NR4A2CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117106189-A Metal organic framework artificial hydrolase and preparation method and application thereof 华南理工大学 2023-11-24 CN claimed
CN-109415327-A Azilsartan intermediate, Azilsartan and their manufacturing method 株式会社德山 2019-03-01 CN claimed
JP-4658940-B2 2011-03-23 JP claimed
JP-2006528213-A 2006-12-14 JP claimed
EP-1636216-A1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS Sanofi-Aventis Deutschland GmbH (DE) 2006-03-22 EP claimed
WO-2004101553-A1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-11-25 WO claimed
US-20260137697-A1 THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF UNIV DE MONTREAL (CA) 2026-05-21 US disclosed
US-20260049074-A1 THIADIAZOLYL DERIVATIVES IDEAYA BIOSCIENCES, INC. (US) 2026-02-19 US disclosed
US-12509454-B2 Thiadiazolyl derivatives IDEAYA BIOSCIENCES, INC. (US) 2025-12-30 US disclosed
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease UNIVERSITE DE MONTREAL (CA) 2025-11-25 US disclosed
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE UNIVERSITE DE MONTREAL (CA) 2025-08-28 US disclosed
EP-4602047-A1 THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF The Universite de Montreal (CA) 2025-08-20 EP disclosed
CN-120035595-A Thiazolo [5,4-d ] pyrimidine compounds, compositions comprising the same and uses thereof 蒙特利尔大学 2025-05-23 CN disclosed
WO-2003106430-A1 BENZIMIDAZOLE INHIBITORS OF POLY(ADP-RIBOSYL) POLYMERASE PFIZER INC. (US) 2003-12-24 WO disclosed
EP-1339402-A2 BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 2003-09-03 EP disclosed
US-20030022883-A1 Compounds and their use EISAI INC. 2003-01-30 US disclosed
WO-2002044183-A2 BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 2002-06-06 WO disclosed
WO-2001074786-A1 HETEROBIARYLSULPHONAMIDES AND THEIR USE AS PDE 7 INHIBITORS DARWIN DISCOVERY LIMITED (GB) 2001-10-11 WO disclosed
US-3988155-A CYANINE SENSITIZING DYES FUJI PHOTO FILM CO., LTD. (JA) 1976-10-26 US disclosed
US-3985563-A Silver halide photographic emulsion FUJI PHOTO FILM CO., LTD. (JA) 1976-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022883-A1 Compounds and their use PARP1, PARP2, PARP3 PARP1 1/4885PKN1 1232/4885PKN2 694/4885
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS PARP1 876/4885PKN1 467/4885PKN2 382/4885
US-20260049074-A1 THIADIAZOLYL DERIVATIVES POLH, POLM, POLD1 PARP1 141/4885PKN1 2422/4885PKN2 2784/4885
US-20260137697-A1 THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF NRAS, KRAS, BRAF PARP1 3128/4885PKN1 1543/4885PKN2 1215/4885
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, DPYD PARP1 861/4885PKN1 461/4885PKN2 367/4885
US-12509454-B2 Thiadiazolyl derivatives POLD1, POLQ, DNA2 PARP1 462/4885PKN1 1454/4885PKN2 2142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.